drug

Pot Smokers May Have Lower Risk of Obesity (LiveScience.com)

LiveScience.com – Despite the tendency of marijuana users to experience the “munchies,” pot smokers may have a lower risk of obesity that those who don’t use the drug, a new study finds.

Excerpt from: 
Pot Smokers May Have Lower Risk of Obesity
(LiveScience.com)

drug

Pot Smokers May Have Lower Risk of Obesity (LiveScience.com)

LiveScience.com – Despite the tendency of marijuana users to experience the “munchies,” pot smokers may have a lower risk of obesity that those who don’t use the drug, a new study finds.

See the original post:
Pot Smokers May Have Lower Risk of Obesity
(LiveScience.com)

drug

U.S. pulls Abbott’s Meridia diet drug off market (Reuters)

Reuters – U.S. health officials have ordered Abbott Laboratories’ controversial weight loss drug Meridia off the market, and the company said it would comply even though it still thinks the drug is safe.

View original here: 
U.S. pulls Abbott’s Meridia diet drug off market
(Reuters)

drug

Weight loss drug shows promise in clinical trial (Reuters)

Reuters – An experimental weight loss drug helped obese people lose more than 10 percent of their weight after two years in a clinical trial, but safety details were scant for the drug made by Vivus Inc, which in July was turned down by a panel of U.S. experts.

Read the original: 
Weight loss drug shows promise in clinical trial
(Reuters)

drug

U.S. panel splits on Abbott diet drug ban (Reuters)

Reuters – A U.S. advisory panel was divided over whether to recommend banning Abbott Laboratories’ controversial weight-loss drug on Wednesday, although most agreed that the drug’s heart risk cast a shadow on its future use.

Original post:
U.S. panel splits on Abbott diet drug ban
(Reuters)

drug

Abbott diet drug study renews calls for U.S. ban (Reuters)

Reuters – A study funded by Abbott Laboratories offered more detailed evidence that its weight-loss drug Meridia increases heart risks, prompting renewed calls by consumer advocates and others to pull the drug from the market.

Originally posted here:
Abbott diet drug study renews calls for U.S. ban
(Reuters)

drug

Abbott’s diet drug study renews calls for U.S. ban (Reuters)

Reuters – A study funded by Abbott Laboratories offered more detailed evidence that its weight-loss drug Meridia increases heart risks, prompting renewed calls by consumer advocates and others to pull the drug from the market.

Original post:
Abbott’s diet drug study renews calls for U.S. ban
(Reuters)

drug

Diet Pill Meridia Ups Heart Attack Risk: Study (HealthDay)

HealthDay – WEDNESDAY, Sept. 1 (HealthDay News) — A new study is linking the popular weight loss drug Meridia to an increased risk of non-fatal heart attacks and stroke, although taking the drug did not seem to up the risk of death in patients with a history of heart problems.

See the rest here:
Diet Pill Meridia Ups Heart Attack Risk: Study
(HealthDay)

drug

Corrected: Abbott’s diet drug study renews calls for U.S. ban (Reuters)

Reuters – A study funded by Abbott Laboratories offered more detailed evidence that its weight-loss drug Meridia increases heart risks, prompting renewed calls by consumer advocates and others to pull the drug from the market.

Original post: 
Corrected: Abbott’s diet drug study renews calls for U.S. ban
(Reuters)

drug

Gene testing could have saved weight-loss drug (Reuters)

Reuters – Genetic testing might have helped identify people who would become depressed or suicidal while taking Sanofi-Aventis’ weight loss drug Acomplia, which might have helped keep the drug on the market, U.S. researchers said on Thursday.

See more here:
Gene testing could have saved weight-loss drug
(Reuters)

Next Page »